| Hemodynamic performance of the Medtronic Mosaic porcine bioprosthesis up to ten years. | |
| | |
MedLine Citation:
|
PMID: 17383332 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The Mosaic bioprosthesis (Medtronic, Minneapolis, MN) is a third-generation stented porcine bioprosthesis combining physiologic fixation and amino oleic acid antimineralization treatment to improve hemodynamic performance and durability. The findings of this single-center experience with this valve were evaluated to determine the clinical and hemodynamic performance. METHODS: Between February 1994 and October 1999, we enrolled 255 patients with aortic valve replacement (AVR) with a mean age of 67 years (range, 23 to 82 years) and 47 patients with mitral valve replacement (MVR) with a mean age of 67 years (range, 41 to 84 years) in this post-United States Food and Drug Administration approval prospective and nonrandomized clinical trial. Patients were followed-up, including serial echocardiographic assessment, within 30 days, at 6 months, and annually thereafter. The cumulative follow-up was 1540 patient-years for AVR (mean, 6.1 years; maximum, 10 years) and 250 patient-years for MVR (mean, 5.4 years, maximum; 10 years). RESULTS: Early mortality after AVR (<30 days) was 0.8%; late mortality per patient-year was 3.5%, including a valve-related/unexplained mortality of 1.1%. Early mortality after MVR (<30 days) was 0.0%; late mortality per patient-year was 2.8%, including a valve-related/unexplained mortality of 1.2%. Median postoperative gradient and effective orifice area for all valves after AVR were (early, n = 252; 5 years, n = 161; 9 years, n = 43) 13.7, 12.3, and 11.7 mm Hg and 1.9, 1.8, and 1.8 cm2 at early, 5 years, and 9 years, respectively. With MVR respective data were (early, n = 46; 5 years, n = 25; 7 years, n = 13) 4.6, 4.1, and 3.9 mm Hg and 1.8, 2.2, and 2.3 cm2. At 10 years, freedom from adverse events in the AVR group and MVR group was, respectively, thromboembolism, 86.6% +/- 6.6% and 86.3% +/- 9.8%; permanent neurologic event, 91.2% +/- 6.8% and 90.9% +/- 8.7%; valve thrombosis, 98.2% +/- 0.8% and 100%; structural valve deterioration, 87.1% +/- 6.7% and 100%. CONCLUSIONS: Our midterm results demonstrate clinical safety and good performance of the Mosaic bioprosthesis. Continued follow-up will determine if this new design will provide increased durability. |
| | |
Authors:
|
Friedrich-Christian Riess; Ralf Bader; Eva Cramer; Lorenz Hansen; Bèr Kleijnen; Gunther Wahl; Jürgen Wallrath; Stephan Winkel; Niels Bleese |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article |
Journal Detail:
|
Title: The Annals of thoracic surgery Volume: 83 ISSN: 1552-6259 ISO Abbreviation: Ann. Thorac. Surg. Publication Date: 2007 Apr |
Date Detail:
|
Created Date: 2007-03-26 Completed Date: 2007-04-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 15030100R Medline TA: Ann Thorac Surg Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1310-8 Citation Subset: AIM; IM |
Affiliation:
|
Albertinen Heart Center, Hamburg, Germany. friedrich-christian.riess@albertinen.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Animals Aortic Valve / physiopathology, surgery* Bioprosthesis* Cardiac Output / physiology Echocardiography, Doppler Female Follow-Up Studies Heart Valve Diseases / mortality*, surgery*, ultrasonography Heart Valve Prosthesis Implantation / adverse effects, methods* Humans Linear Models Male Middle Aged Mitral Valve / physiopathology, surgery* Postoperative Care Postoperative Complications Probability Prospective Studies Prosthesis Design Prosthesis Failure Risk Assessment Severity of Illness Index Survival Rate Swine Treatment Outcome |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Edge-to-edge mitral repair without annuloplasty in combination with surgical ventricular restoration...
Next Document: Ten-year experience with the Cox-maze procedure for atrial fibrillation: how do we define success?